Quick Answer: CAR-T for Lymphoma in China, 2026
CAR-T therapy for relapsed/refractory lymphoma in China costs $89,000-$151,000 (commercial) or $30,000-$80,000 (clinical trial) — 60-85% below US pricing and roughly 40-60% below Singapore, with no waitlist for eligible patients (most slots book 2-4 weeks after eligibility is confirmed). China has more NMPA-approved CAR-T products than the US or EU, and CD19 CAR-T for DLBCL — the most common lymphoma — is available at multiple top-tier hematology centers with English-speaking international departments. The full journey, from records review to infusion, takes about 4-6 weeks in China.
1. How Much Does CAR-T for Lymphoma Cost in China? (2026)
CAR-T pricing in China has two tiers, which is why quotes for the same therapy can differ by 3-5x between patients.
| Access Route | 2026 Price (USD) | Best For |
|---|---|---|
| Commercial (NMPA-approved CD19 CAR-T) | $89K – $151K | Patients who want an approved product with no trial eligibility requirements |
| Clinical trial / sponsored access | $30K – $80K | Eligible patients willing to enroll in a hospital- or manufacturer-sponsored trial |
China vs Singapore vs India vs US (CD19 CAR-T for Lymphoma)
| Country | Commercial Price (USD) | Notes |
|---|---|---|
| China | $89K – $151K | Carteyva (relmacabtagene) and Yescarta-type CD19 products; 7 NMPA-approved CAR-T products total |
| Singapore | $280K – $350K | Kymriah available; no domestic CAR-T manufacturing |
| India | Not approved commercially | Trial access only; limited slots |
| USA | $300K – $500K | Yescarta, Kymriah, Breyanzi, Carvykti — plus hospitalization costs |
2026 estimates based on published pricing. China's cost advantage comes from domestic manufacturing (Carteyva is China-developed) and lower hospitalization costs. Travel and accommodation are not included in either figure.
Full Trip Budget for International Lymphoma Patients
| Item | Estimated Cost (USD) |
|---|---|
| Medical visa + invitation letter | $0 – $140 |
| Round-trip flights (Asia → China) | $400 – $1,500 |
| Hospital deposit (payable on admission) | 30-50% of quoted CAR-T cost |
| Hospital stay (4-6 weeks, incl. monitoring) | Included in CAR-T package |
| Companion accommodation | $1,500 – $4,000 |
| Translator / medical coordinator | $500 – $2,000 |
| Post-treatment follow-up scans (3, 6, 12 months) | $1,000 – $3,000 |
| Total trip (excluding CAR-T) | $3,500 – $10,500 |
2. Top 4 Hospitals for CAR-T Lymphoma Treatment in China
All listed hospitals have dedicated hematology departments with international patient offices and English-speaking coordinators.
1. Ruijin Hospital — Shanghai Jiao Tong University School of Medicine
| Field | Detail |
|---|---|
| Official English name | Ruijin Hospital, Shanghai Jiao Tong University School of Medicine |
| Specialties | Hematology (#1 in China, Fudan Ranking), CD19 CAR-T for DLBCL/ALL, BCMA CAR-T for myeloma |
| International patient services | Yes — dedicated international department, English team, visa invitation letters in 48 hours |
| Cost range | $89K – $130K commercial; trial slots frequently open for relapsed DLBCL |
| Waiting time | 2-4 weeks after eligibility confirmed (commercial); 4-8 weeks (trial) |
| Why recommended | One of the largest CAR-T programs in Asia; strong published outcomes for DLBCL; high trial availability |
2. Peking University Cancer Hospital
| Field | Detail |
|---|---|
| Official English name | Peking University Cancer Hospital |
| Specialties | Oncology (top 3 nationally), lymphoma CAR-T programs, solid-tumor CAR-T (satri-cel) |
| International patient services | Yes — visa support, English / Arabic / Russian coordinators |
| Cost range | $89K – $120K hematologic CAR-T |
| Waiting time | 2-4 weeks (commercial) |
| Why recommended | National oncology reference center; lymphoma and leukemia CAR-T programs co-located; experienced with international lymphoma referrals |
3. Jiahui International Hospital (Shanghai)
| Field | Detail |
|---|---|
| Official English name | Jiahui International Hospital |
| Specialties | International-standard private hospital; CAR-T infusion and monitoring; lymphoma care |
| International patient services | Yes — full English-speaking environment; halal meals and prayer space for Middle Eastern patients |
| Cost range | $110K – $170K; bundled pricing includes coordinator and case management |
| Waiting time | 2-3 weeks (commercial) |
| Why recommended | Best choice for patients prioritizing English-speaking care and a private-hospital environment; transparent bundled quotes |
4. Tongji Hospital — Huazhong University of Science & Technology
| Field | Detail |
|---|---|
| Official English name | Tongji Hospital, Tongji Medical College, HUST |
| Specialties | Hematologic malignancies (top 10 nationally), high-volume lymphoma program |
| International patient services | Yes — English and Russian support |
| Cost range | $75K – $115K commercial — among the most competitive hematologic CAR-T pricing in China |
| Waiting time | 2-4 weeks (commercial) |
| Why recommended | Significantly lower pricing than Tier-1 city hospitals with comparable program volume; good option for budget-conscious international patients |
Not sure if your case qualifies? Send the latest pathology report (within 3 months) plus CD19/CD20 antigen status and imaging — we route your case to the right hematology center within 48 hours and get a written quote back. Get a free hospital recommendation and cost estimate → Start Free Case Review (We reply within 24 hours · 100% confidential · No obligation).
3. Why China for CAR-T Lymphoma Treatment?
| Factor | Detail |
|---|---|
| Approved products | 7 NMPA-approved CAR-T products as of mid-2026 — more than the US (6) or EU (5); Carteyva (relmacabtagene) is China-developed for DLBCL |
| Cost advantage | 60-85% below US prices; 40-60% below Singapore; domestic manufacturing keeps product cost down |
| Trial access | 500+ active CAR-T trials globally — the largest pipeline is in China; DLBCL trial slots are among the most available |
| No waitlist | Commercial slots book in 2-4 weeks after eligibility; trial enrollment 4-8 weeks |
| Volume | Tier-1 hematology centers perform 200-400+ CAR-T infusions per year — comparable to MD Anderson or Memorial Sloan Kettering |
4. Treatment Timeline: From Contact to Infusion
| Phase | What Happens | Duration |
|---|---|---|
| 1. Records review (free) | Send pathology report, antigen status (CD19), imaging, prior treatment lines | 48 hours |
| 2. Eligibility + quote | Hospital confirms eligibility; written commercial quote in 7-10 working days; parallel trial options listed | 1-2 weeks |
| 3. Deposit & slot | 30-50% deposit locks the manufacturing slot (commercial); or informed consent for trial | 1 week |
| 4. Visa & travel | Hospital issues medical visa invitation letter; travel to China | 2-4 weeks |
| 5. Apheresis | T-cells collected (1 day outpatient procedure) | Day 1 |
| 6. Manufacturing | CAR-T cells manufactured (China domestic: faster turnaround) | 2-4 weeks |
| 7. Conditioning + infusion | 3-5 days lymphodepleting chemo, then 1-day infusion | 1 week |
| 8. Monitoring | Inpatient monitoring for CRS and side effects | 10-14 days |
| 9. Follow-up & return | 30-day medication plan; tele-consults with the China team for the first year | Ongoing |
Total China stay: 4-6 weeks.
5. Real Patient Example
A 58-year-old patient from Southeast Asia with relapsed DLBCL — after two prior chemotherapy lines failed — was assessed at Ruijin Hospital in Shanghai. She enrolled in a CD19 CAR-T trial, completed apheresis and infusion within five weeks, and was discharged with a 30-day medication plan. Follow-up scans at 3 and 6 months were coordinated between her local oncologist and the Ruijin team via tele-consult.
More patient journeys: Margaret's cataract surgery in Shanghai · David's lung cancer treatment
6. Frequently Asked Questions
How much does CAR-T therapy for lymphoma cost in China in 2026?
Commercial CD19 CAR-T for lymphoma costs $89,000-$151,000 in China. Clinical trial access can reduce this to $30,000-$80,000 for eligible patients. The same therapy costs $300,000-$500,000 in the US and $280,000-$350,000 in Singapore. (2026 estimates based on published data; final cost depends on hospital and case complexity.)
Which lymphoma patients are eligible for CAR-T in China?
Most programs target relapsed or refractory DLBCL after at least two prior lines of therapy, plus other CD19-positive subtypes (follicular lymphoma, mantle cell lymphoma). Requirements include CD19 expression, adequate organ function, and reasonable performance status. A free case review determines eligibility.
Which hospitals in China offer CAR-T for lymphoma?
Ruijin Hospital (Shanghai), Peking University Cancer Hospital (Beijing), Jiahui International Hospital (Shanghai), and Tongji Hospital (Wuhan) are the top choices for international lymphoma patients. All have international departments with English-speaking coordinators and visa support.
How long does CAR-T treatment for lymphoma take in China?
4-6 weeks in China: apheresis (1 day) → manufacturing (2-4 weeks) → conditioning chemo (3-5 days) → infusion (1 day) → monitoring (10-14 days). Add 2-4 weeks before for visa and travel.
Is CAR-T for lymphoma safe in China?
At JCI-accredited or NMPA-certified centers, outcomes are comparable to international standards. Commercial products are NMPA-approved; trial products follow ICH-GCP guidelines. International departments provide English-speaking care, CRS management, and ICU monitoring on-site.
Get a Free Hospital Recommendation & Cost Estimate
Send us the latest pathology report — we'll check eligibility across commercial and trial routes, match you with 2-3 suitable hematology centers, and get written quotes. No obligation, 100% confidential, we reply within 24 hours.
- 📧 Email: contact@chinahospitalsguide.com
- 💬 WhatsApp: +86 157 6310 7083
- 📨 Telegram: @chinahospitalguide
- 💬 WeChat: chinahospitalguide
- 🌐 Start Free Case Review
Related Reading
- CAR-T Therapy Cost in China 2026 (Full Price Guide)
- Solid Tumor CAR-T in China — Satri-cel Guide
- CAR-T Therapy Hospitals in China
- Cancer Treatment Cost in China 2026
- For Russian-speaking patients: лечение рака в Китае
- For Arabic-speaking patients: العلاج في الصين
- For Indonesian patients: Panduan Berobat di Tiongkok